Lupin has been trying for two years to bring its plant in Goa, India, up to FDA standards, but a new warning letter says more improvements are needed.

Cardinal Health has agreed to sell its China business to Shanghai Pharma for $557 million in cash.

With expansion projects coming to fruition at a Pfizer plant in Michigan, the company expects to hire 200 workers next year.

With its global expansion dragging on earnings, Swedens Recipharm will will close two plants in Sweden and lay off 225 workers.

EU drugmakers are warning of drug supply chaos if the U.K. and European Commission can’t strike a specific deal in advance of the Brexit deadline.

Seqirus will invest £40 million into its U.K. site, adding about 100 jobs so it can shorten production time for its Fluad influenza vaccine.

The FDA has slapped a warning letter on a Chinese company that shipped multiple lots of an OTC product to the U.S. that contained the wrong API.

A Danish medicines repackager has again had its manufacturing certificate yanked by regulators just months after it said it had resolved its problems.

Manufacturing